CenExel iResearch an
CenExel iResearch and CenExel ACMR Unveil Dedicated PET Scan Unit for Specialized Research
03 sept. 2024 09h00 HE | CenExel Clinical Research
Atlanta, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- CenExel iResearch and CenExel ACMR, two premier Centers of Excellence located in Atlanta, Georgia, are thrilled to announce the launch of a dedicated...
Picture1.jpg
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
17 juin 2024 08h51 HE | Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Picture1.jpg
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
17 juin 2024 08h51 HE | Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
22157.jpg
UK's First National Total-Body PET Imaging Platform Boosts Demand for Expert PET Market Insights
11 oct. 2023 08h43 HE | Research and Markets
Dublin, Oct. 11, 2023 (GLOBE NEWSWIRE) -- As the UK takes a monumental leap towards advanced medical imaging with the unveiling of the National PET Imaging Platform (NPIP), industry professionals,...
Curium Receives Posi
Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent
26 mai 2023 03h42 HE | Curium
If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional...
Curium Announces Las
Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
23 mai 2023 12h57 HE | Curium
PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety,...
22157.jpg
2023 United States PET Imaging Market Report: Forecasts to 2026 with Focus on Market Trends in Hospitals and Imaging Centers, Including Procedure Volume, Use of OEM Vs. Third-Party Service Providers and More
06 avr. 2023 04h18 HE | Research and Markets
Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "2023 U.S PET Imaging Market Summary Report" report has been added to ResearchAndMarkets.com's offering. This '2023 PET Imaging Market Summary...
Curium Confirms No S
Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial
14 mars 2023 10h46 HE | Curium
To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in...
MicrosoftTeams-image (5).png
Germanium-68/ Gallium-68 Generators Market to Reach US$ 140.7 Mn by 2031, TMR Study
13 déc. 2022 12h30 HE | Transparency Market Research
Wilmington, Delaware, United States, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - According to a market report by TMR, the global germanium-68/gallium-68 generators industry...
Global Diagnostic Imaging Services Market
Global Diagnostic Imaging Services Market Report 2022: Technological Advancements in Diagnostic Imaging to Shape Sector Moving Forward
20 oct. 2022 04h58 HE | Research and Markets
Dublin, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Diagnostic Imaging Services Market by Procedure (MRI, Ultrasound, CT, X-RAY, Nuclear Imaging, Mammography), Application (OB/Gyn, Pelvic/Abdomen,...